Riociguat for the treatment of pulmonary hypertension

Bibliography

• Simonneau G, Robbins IM, Beghetti M, Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl 1):S43-54
   PubMed Web of Science ®Google Scholar
• Cogan JD, Pauciulo MW, Batchman AP, High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:590-8
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S
   PubMed Web of Science ®Google Scholar
• Morrell NW, Adnot S, Archer SL, Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl 1):S20-31
   PubMed Web of Science ®Google Scholar
• Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008;118:2372-9
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M. Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest 2002;122(Suppl 6):326S-334S
   PubMed Web of Science ®Google Scholar
• Tuder R, Voelkel N. Pulmonary hypertension and inflammation. J Lab Clin Med 2010;132:16-24
   Web of Science ®Google Scholar
• Sitbon O, Humbert M, Jais X, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Wiedemann R, Rose F, Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900
   PubMed Web of Science ®Google Scholar
• Galie N, Hoeper MM, Humbert M, Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537
   PubMed Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG, Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44
   PubMed Web of Science ®Google Scholar
• Bhatia S, Frantz RP, Severson CJ, Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003;78:1207-13
   PubMed Web of Science ®Google Scholar
• Chockalingam A, Gnanavelu G, Venkatesan S, Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005;99:91-5
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Negro L, A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Barbera JA, Channick RN, Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl 1):S85-96
   PubMed Web of Science ®Google Scholar
• Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007;96:527-41
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-13
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Schermuly RT, Weissmann N, Reverse remodeling – paradigm shift in the treatment of pulmonary hypertension. Dtsch Med Wochenschr 2006;131:871-4
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5:689-702
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Pepke-Zaba J, Barbera JA, Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):68S-72S
   PubMed Web of Science ®Google Scholar
• Grimminger F, Spriestersbach R, Weissmann N, Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol 1995;78:1509-15
   PubMed Web of Science ®Google Scholar
• Derbyshire ER, Marletta MA. Biochemistry of soluble guanylate cyclase. Handb Exp Pharmacol 2009;191:17-31
   PubMedGoogle Scholar
• Dumitrascu R, Weissmann N, Ghofrani HA, Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-95
   PubMed Web of Science ®Google Scholar
• Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta 1999;1411:334-50
   PubMed Web of Science ®Google Scholar
• Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987;39:163-96
   PubMed Web of Science ®Google Scholar
• Zabel U, Hausler C, Weeger M, Schmidt HH. Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione s-transferase affinity tag. J Biol Chem 1999;274:18149-52
   PubMed Web of Science ®Google Scholar
• Wedel B, Humbert P, Harteneck C, Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc Natl Acad Sci USA 1994;91:2592-6
   PubMed Web of Science ®Google Scholar
• Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003;93:96-105
   PubMed Web of Science ®Google Scholar
• Hoffmann LS, Schmidt PM, Keim Y, Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol 2009;157:781-95
   PubMed Web of Science ®Google Scholar
• Melichar VO, Behr-Roussel D, Zabel U, Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 2004;101:16671-6
   PubMed Web of Science ®Google Scholar
• Stasch JP, Schmidt PM, Nedvetsky PI, Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-61
   PubMed Web of Science ®Google Scholar
• Evgenov OV, Pacher P, Schmidt PM, NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-68
   PubMed Web of Science ®Google Scholar
• Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009;(191):277-308
   PubMedGoogle Scholar
• Evgenov OV, Kohane DS, Bloch KD, Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007;176:1138-45
   PubMed Web of Science ®Google Scholar
• Krasuski RA, Warner JJ, Wang A, Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 2000;36:2204-11
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Kreisselmeier KP, Ghofrani HA, Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45
   PubMed Web of Science ®Google Scholar
• Black SM, Sanchez LS, Mata-Greenwood E, sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;281:L1051-7
   PubMed Web of Science ®Google Scholar
• Giordano D, De Stefano ME, Citro G, Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 2001;1539:16-27
   PubMed Web of Science ®Google Scholar
• Hanson KA, Burns F, Rybalkin SD, Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 1998;158:279-88
   PubMed Web of Science ®Google Scholar
• Maclean MR, Johnston ED, McCulloch KM, Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997;283:619-24
   PubMed Web of Science ®Google Scholar
• Wharton J, Strange JW, Moller GM, Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:105-13
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57
   PubMed Web of Science ®Google Scholar
• Ko FN, Wu CC, Kuo SC, YC-1, a novel activator of platelet guanylate cyclase. Blood 1994;84:4226-33
   PubMed Web of Science ®Google Scholar
• Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998;53:123-7
   PubMed Web of Science ®Google Scholar
• Friebe A, Schultz G, Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J 1996;15:6863-8
   PubMed Web of Science ®Google Scholar
• Stasch JP, Becker EM, Alonso-Alija C, NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212-15
   PubMed Web of Science ®Google Scholar
• Evgenov OV, Ichinose F, Evgenov NV, Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004;110:2253-9
   PubMed Web of Science ®Google Scholar
• Deruelle P, Balasubramaniam V, Kunig AM, BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 2006;90:135-44
   PubMedGoogle Scholar
• Mittendorf J, Weigand S, Alonso-Alija C, Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009;4:853-65
   PubMed Web of Science ®Google Scholar
• Frey R, Muck W, Unger S, Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008;48:926-34
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Stasch JP, Pullamsetti SS, Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32:881-91
   PubMed Web of Science ®Google Scholar
• Frey R, Muck W, Unger S, BAY 63-2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers. BMC Pharmacol 2007;7(Suppl 1): abstract P20
   Google Scholar
• Grimminger F, Weimann G, Frey R, First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785-92
   PubMed Web of Science ®Google Scholar
• Frey R, Muck W, Kirschbaum N, Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol 2010: published online 27 August 2010, doi: 10.1177/0091270010378119
   Google Scholar
• Ghofrani HA, Hoeper MM, Halank M, Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-9
   PubMed Web of Science ®Google Scholar
• Ghofrani A, Hoeper M, Halank M, Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: first long-term extension data from a Phase II study. Am J Respir Crit Care Med 2010;181:A6770
   Web of Science ®Google Scholar
• Hoeper M, Halank M, Wilkens H, Riociguat for patients with pulmonary hypertension associated with interstitial lung disease. Am J Respir Crit Care Med 2010;181:A2562
   Web of Science ®Google Scholar